Autoimmune bullous disease including pemphigus group and pemphigoid group
Conditions
Interventions
Imatinib 800 mg a day p.o. for seven days will be started within 14 days of starting steroid therapy (and when the bed is secured). Imatinib 800 mg a day p.o. for seven days will be started afterregis
Sponsors
Kabashima Kenji
Endo Yuichiro
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Eligibility (inclusion) criteria 1) Diagnosed as pemphigus group or pemphigoid group. 2) Those who are not expected to be treated with pulse steroid therapy or intravenous immunoglobulin (IVIG). 3) The age at the time of consent acquisition is 20 or over 20 years old. 4) The latest blood test and liver function test within 4 weeks before registration satisfy all of the following: Neutrophil count >= 1,500/mm3; platelet count >= 75,000/mm3; AST (GOT) < 120 IU/L; ALT(GPT) < 120 IU/L; total bilirubin < 1.8 mg/dL. 5) Males, those agreeing to contraception for 4 weeks from the start of the test drug administration to the final administration day of the test drug. Females, those after surgical contraceptive surgery such as postmenopausal (more than one year since the last menstruation), or bilateral oophorectomy. 6) Written informed consent by the patient has been obtained.
Exclusion criteria
Exclusion criteria: Exclusion criteria 1) No history of allergy to Imatinib. 2) Those who have one of the following complications: Serious heart disease, serious liver disorder, serious renal disorder or past history of such conditions. 3) Those who had given consent of participation in other trials within 4 weeks before the acquisition of this study. 4) Those who are judged to be unsuitable for carrying out this study by the investigator or shared medical doctors.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PDAI/BPDAI | — |
Secondary
| Measure | Time frame |
|---|---|
| Titers of autoantibodies in serum. Titers of antibodies in other body fluids including saliva and blister contents. | — |
Contacts
Public ContactTakashi Nomura
Kyoto University Hospital
Outcome results
None listed